Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

When hospitals follow the guidelines deaths from heart attack are halved

A study by an international team of researchers say they have found that deaths from severe heart attacks after hospital admission have almost halved in six years.

2 May 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

25 Apr 2007

Sticking with guidelines for acute coronary syndromes benefits even very elderly patients

Some say age 90 is the new age 70. If so, there's never been a better time for elderly patients to discuss with family and physicians just how aggressive medical care should be in case of a threatened or definite heart attack.

24 Apr 2007

Migraine associated with increased risk of subsequent major cardiovascular disease in men

Men with migraine headaches may be at an increased risk for major cardiovascular disease and especially heart attacks, according to a report in the April 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Apr 2007

GP surgeries with specialist nurses can help save lives

One of the biggest research trials carried out in GP surgeries has confirmed that those with specialist cardiac nurse clinics can help to improve patients' lives.

24 Apr 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

All physicians involved in the treatment of PBS/IC understand that the placebo effect likely plays a major role in treatment, and is important when evaluating drug trials.

19 Apr 2007

New research fails to verify gene variations as risk factors for acute coronary syndromes

New research has failed to confirm findings from smaller studies that 85 gene variations are associated with an increased risk for acute coronary syndromes (ACS), which includes heart attack and a type of angina, according to a study in the April 11 issue of JAMA.

11 Apr 2007

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Percutaneous coronary interventions (PCI) involve opening partially blocked arteries to improve blood flow to the heart. These procedures are performed more than 1 million times a year.

3 Apr 2007

Coronary procedure adds no benefit over 'optimal medical therapy' alone

Percutaneous coronary intervention plus optimal medical therapy does not improve outcomes in patients with coronary artery disease, compared with optimal medical therapy alone, according to study results presented at the 56th Annual Scientific Session of the American College of Cardiology in New Orleans, and published online in the New England Journal of Medicine.

1 Apr 2007

Novel anti-oxidant and anti-inflammatory agent reduces coronary events

Heart attacks are caused by a build-up and instability of plaque in the coronary arteries, which is often a result of chronic inflammation of the blood vessel walls.

31 Mar 2007

FDA announces marketing halt for GI drug, Zelnorm

The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States.

30 Mar 2007

Angioplasty doesn't outweigh medicine in study

In what some leading cardiologists are calling a "blockbuster" study, new research could alter the approach to treating patients who have cardiovascular disease but may not be at immediate risk of heart attack or stroke.

30 Mar 2007

London asthma sufferers get space-based help

The city of London has launched an innovative service, funded by ESA, which delivers air pollution alerts and health advice via SMS text messages to those who suffer from asthma and other conditions vulnerable to poor air quality.

29 Mar 2007

Medications plus lifestyle changes work as well as angioplasty to reduce deaths in stable heart-disease patients

Coronary revascularization with stenting or balloon angioplasty combined with optimal medical therapy is no more effective in preventing a heart attack, other major cardiovascular events or death in patients with stable heart disease, than optimal medical therapy alone, results of a new study conducted in 50 hospitals in the U.S. and Canada has shown.

27 Mar 2007